What could possibly go wrong?
On May 2nd, 2023 Meat & Livestock Australia company published a statement titled “MLA funds mRNA technology project to rapidly produce emergency animal disease vaccines”.
Excerpts:
“This project will develop a mRNA vaccine pipeline initially for LSD, but potentially for other emergency diseases,” Michael said.
“This will enable capacity for rapid mass production of a vaccine for LSD in the event of an outbreak.
“No LSD vaccines are registered for use in Australia yet. While some killed vaccines exist overseas, the path to registration in Australia for traditionally-produced is longer than that of an mRNA vaccine.”
“ Australia faces increasing biosecurity threats to its animal populations which have far reaching economic, social and animal welfare impacts. Next-generation (mRNA-based) vaccine technologies may provide a game-changing approach to emergency disease preparedness.
““Live vaccines cannot be imported to Australia. The establishment of the capacity to produce a vaccine for LSD is the priority that will provide the Australian cattle and other ruminant industries with insurance against an imminent biosecurity threat that would have far reaching trade, animal health and economic implications.”
“The establishment of an mRNA production capability and development of an LSD vaccine will be the initial flagship, stand-alone project within a larger program: Adoption of RNA technology to rapidly produce vaccines for emergency animal disease.”
“The larger program unites a network of expertise to bring the advantages of next-generation vaccine technologies to the livestock industries and potentially provide a game-changing solution to enhance biosecurity in Australia”
“The proposed over-arching five-year program will secure licenced mRNA vaccine technology and activate an independent livestock vaccine development and production pathway based on newly established scientific capacity and infrastructure”
What could possibly go wrong?
“ As described on Merck’s animal health website: “A revolutionary swine vaccine platform, SEQUIVITY harnesses RNA particle technology to create customized prescription vaccines against strains of influenza A virus in swine, porcine circovirus (PCV), rotavirus and beyond. It’s supported by a sophisticated dashboard filled with comprehensive data and insights … “The very first RNA-based livestock vaccine, a swine influenza (H3N2) RNA shot, was licensed over a decade ago in 2012, and was developed by Harris vaccines. The company followed up with an avian influenza mRNA shot in 2015. Harris vaccines was acquired by Merck Animal Health later that year.” :
Nelle's journey 